Best Practice Manufacturing and Quality Standards for Bacteriophage Therapy Products: Australian Consensus Statements
Watts, K.; Lin, R. C.; Lynch, S.; Warning, J.; Barr, J. J.; Ben Zakour, N.; Campbell, A.; Chan, J.; Collie, L.; Hedges, M.; Hudson, B.; Irwin, A.; Khatami, A.; Kicic, A.; Laucirica, D.; Lauter, C.; Ling, K.-m.; Ng, R.; Pavuk, N.; Rahmatullah, R.; Sinclair, H.; Tucker, E.; Vreugde, S.; Warner, M.; Velickovic, Z.; iredell, j.
Show abstract
Objective As antimicrobial resistance (AMR) continues to threaten global public health, bacteriophage therapy products (BTPs) offer a promising alternative to conventional antimicrobials. However, translation into routine clinical practice requires best practice standards for manufacturing and quality control to ensure the consistent safety, quality, and reliability of personalised BTPs produced for individual patients or small cohorts. Design A modified Delphi methodology was used to develop consensus statements, engaging experts from Australia's National Bacteriophage Therapy Regulatory Working Group across the fields of clinical microbiology, phage biology, good manufacturing practice (GMP), regulatory science, and government. The process comprised three iterative phases: (1) structured statement development, (2) an anonymous REDCap survey, and (3) a hybrid consensus meeting. The strength of evidence and recommendations was assessed using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework. Results Consensus was reached on 35 statements to provide best practice manufacture and quality control guidance for BTPs. These statements address requirements for phage identification and characterisation; define the point at which GMP-aligned processes commence for ubiquitous phages; outline quality control expectations for phage active pharmaceutical ingredient (pAPI) production and maintenance of BTP and host cell repositories. Additional guidance covers quality management systems, including documentation, traceability, and governance. Conclusion These consensus statements provide comprehensive best practice recommendations for the manufacture and quality control of BTPs in Australia. By promoting consistent, safe, and quality-assured approaches to personalised BTPs, they aim to facilitate clinical implementation while remaining aligned with existing international pharmacopoeial standards and regulatory frameworks.
Matching journals
The top 10 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Establishing defined daily doses (DDDs) for antimicrobial agents used for pigs, cattle and poultry in Japan and comparing them with European DDD values 92%
- Examination of a first-in-class bis-dialkylnorspermidine-terphenyl antibiotic in topical formulation against mono and polymicrobial biofilms 91%
- Antimicrobial use in laboratory rodent facilities in Australia and New Zealand- a cross-sectional survey of veterinarians and facility managers 91%
Similar papers in this journal
- Health Information Exchanges (HIEs) as Novel Sources for Population-Based Post Marketing Surveillance of Medical Products: A Pilot Study from the FDA Sentinel Innovation Center 89%
- Standardization of drug names in the FDA Adverse Event Reporting System: The DiAna dictionary 89%
- Sales of over-the-counter products containing codeine in 31 countries, 2013-2019: a retrospective observational study 88%
Similar papers in this journal
- Clinical Phage Microbiology:A suggested framework and recommendations for the in-vitro matching steps of phage therapy 92%
- Dynamics of mcr-1 prevalence and mcr-1-positive Escherichia coli after the cessation of colistin use as a feed additive for animals in China: a prospective cross-sectional and whole genome sequencing based molecular epidemiological study 88%
- Air and surface sampling for monkeypox virus in UK hospitals 88%
Similar papers in this journal
- Validation of selective agars for detection and quantification of Escherichia coli resistant to critically important antimicrobials 90%
- Evaluating mono and combination therapy of meropenem and amikacin against Pseudomonas aeruginosa bacteremia in the Hollow-Fiber Infection Model 90%
- Generation of false positive SARS-CoV-2 antigen results with testing conditions outside manufacturer recommendations: A scientific approach to pandemic misinformation 89%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.